RenovoRx (NASDAQ:RNXT) Posts Earnings Results, Meets Estimates

RenovoRx (NASDAQ:RNXT) released its earnings results on Thursday. The company reported ($0.08) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.08), FiscalAI reports. The firm had revenue of $0.56 million for the quarter, compared to analyst estimates of $0.47 million. RenovoRx had a negative net margin of 994.48% and a negative return on equity of 119.77%.

Here are the key takeaways from RenovoRx’s conference call:

• RenovoRx reported record Q1 2026 revenue of $563,000, up 136% sequentially from Q4 2025 and more than half of full-year 2025 revenue, signaling that its commercial model is starting to scale.
• The company said it now has 16 active commercial cancer centers as of May 2026, up from 8 at year-end 2025, with 32 more centers in the pipeline and a target of 36 centers by year-end.
• Management reiterated full-year 2026 revenue guidance of $3 million to $4 million and said second-quarter revenue is tracking above Q1, which they believe keeps them on plan.
• The TIGeR-PaC Phase III trial is nearing enrollment completion, with 106 of 114 patients randomized and enrollment expected to close in early June, while final data remains expected in mid-to-late 2027.
• RenovoRx completed an oversubscribed $10 million private placement and ended Q1 with $12.4 million in cash, giving it runway into the second half of 2027 as it works toward cash flow breakeven.

RenovoRx Stock Up 0.8%

RNXT traded up $0.01 on Thursday, reaching $0.86. The company’s stock had a trading volume of 170,100 shares, compared to its average volume of 277,991. The stock has a 50 day moving average of $0.94 and a two-hundred day moving average of $0.94. The company has a market capitalization of $38.52 million, a price-to-earnings ratio of -2.67 and a beta of 1.00. RenovoRx has a fifty-two week low of $0.70 and a fifty-two week high of $1.45.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. JonesTrading upgraded shares of RenovoRx to a “strong-buy” rating in a report on Thursday, January 29th. Ascendiant Capital Markets raised their price objective on shares of RenovoRx from $13.00 to $13.50 and gave the company a “buy” rating in a report on Thursday, April 9th. Wall Street Zen cut shares of RenovoRx from a “hold” rating to a “strong sell” rating in a research report on Saturday, April 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of RenovoRx in a research note on Wednesday, April 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, RenovoRx has a consensus rating of “Moderate Buy” and an average target price of $8.25.

Institutional Trading of RenovoRx

Several institutional investors have recently modified their holdings of the stock. XTX Topco Ltd boosted its holdings in shares of RenovoRx by 58.6% in the 4th quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock valued at $42,000 after buying an additional 18,525 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in RenovoRx during the 2nd quarter worth $98,000. Citadel Advisors LLC acquired a new stake in RenovoRx during the 3rd quarter worth $154,000. Wealthspire Advisors LLC purchased a new stake in RenovoRx in the fourth quarter valued at $212,000. Finally, Geode Capital Management LLC lifted its position in RenovoRx by 9.9% in the second quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock valued at $467,000 after acquiring an additional 31,730 shares during the last quarter. Hedge funds and other institutional investors own 3.10% of the company’s stock.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.